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Interferon-induced protein of 10 kDa (IP-10) induces
antitumor immunity. Cyclooxygenase-2 and its meta-
bolite prostaglandin E2 (PGE2) are overexpressed in tu-
mor cells, which may suppress antitumor immunity.We
examined the in vitro e¡ects of cyclooxygenase-2 inhibi-
tor NS398 on IP-10 production in human epidermoid
carcinoma A431. NS398 enhanced interferon-c-induced
IP-10 secretion, mRNA expression, and promoter acti-
vation in A431, and exogenous PGE2 antagonized the
enhancement. Interferon-stimulated response element
(ISRE) on IP-10 promoter was responsible for the tran-
scriptional regulation by NS398 and PGE2. NS398 en-
hanced interferon-c-induced transcription through
ISRE and binding of signal transducer and activator of
transcription 1a (STAT1a to ISRE in A431, and PGE2
antagonized the enhancement. NS398 enhanced inter-
feron-c-induced tyrosine phosphorylation of STAT1a,
Janus tyrosine kinase 1, and Janus tyrosine kinase 2,
and PGE2 antagonized the enhancement. PGE2-
mediated suppression of IP-10 synthesis was counter-
acted by adenylate cyclase inhibitor SQ22536 and pro-
tein kinase A inhibitor H-89, and PGE2 receptor EP4
antagonist AH23848B. AH23848B, SQ22536, and H-89
counteracted the PGE2-mediated suppression of ISRE-
dependent transcription, STAT1a binding to ISRE, and
tyrosine phosphorylation of STAT1a, Janus tyrosine ki-
nase 1, and Janus tyrosine kinase 2. PGE2 increased in-
tracellular cAMP level and protein kinase A activity in
A431 pretreated with NS398, and AH23848B blocked
the e¡ects of PGE2. These results suggest that A431-de-
rived PGE2 may generate cAMP signal via EP4 in A431,
which may activate protein kinase A, and may resul-
tantly inhibit interferon-c-induced STAT1a activation
and IP-10 synthesis. The results also suggest that NS398
may restore IP-10 synthesis by preventing PGE2
production in A431 and thus may be therapeutically
useful for skin cancer. Key words: cAMP/protein kinase
A/STAT1a. J Invest Dermatol 119:1080 ^1089, 2002
T
he production of prostaglandin E2 (PGE2) is en-
hanced in a variety of human malignancies (Muller-
Decker et al, 1995). Tumor-derived PGE2 inhibits
antitumor immunity; PGE2 enhances the production
of immunosuppressive interleukin-10 by macro-
phages (Strassmann et al, 1994) and inhibits their production of
interleukin-12, which enhances cytotoxic activity of natural killer
cells and cytotoxicTcells (Tineke et al, 1995). PGE2 inhibits inter-
leukin-2 and interferon-g (IFN-g) production in T cells and nat-
ural killer cells (Anastassiou et al, 1992), and inhibits their
cytotoxic activity (Uoita, 1996). Four subtypes of PGE2
receptor have been identi¢ed, EP1, EP2, EP3, and EP4, and the
immunosuppressive e¡ects of PGE2 are mainly mediated by EP2
or EP4 (Uoita, 1996). EP2 and EP4 are linked to adenylate cyclase
(AC) via guanine nucleotide-binding protein (G-protein)
stimulatory subunit (Gs). The stimulation of EP2 or EP4 gener-
ates 30,50 -adenosine cyclic monophosphate (cAMP), the AC pro-
duct, and activates cAMP-dependent protein kinase (protein
kinase A; PKA) (Uoita, 1996), which leads to the repression of
tumor-suppressive cytokine or chemokine production (Uoita,
1996).
The synthesis of PGs is dependent on the activity of cyclooxy-
genase (COX), which converts arachidonic acid to PGH2. There
are two isoforms of COX: COX-1 and COX-2. COX-1 is consti-
tutively expressed whereas COX-2 is induced by phorbol
esters, endotoxins, or growth factors (Tang et al, 2001). COX-2 ex-
pression is enhanced in malignant epithelial tumors (Muller-
Decker et al, 1999; Gallo et al, 2001), which may result in PGE2
overproduction (Muller-Decker et al, 1995). A recent study
reported that COX-2-inhibiting agents in vivo restored interleu-
kin-12 production and inhibited interleukin-10 production in
macrophages or lymphocytes by preventing PGE2 production
and inhibited the progression of murine lung carcinoma (Stolina
et al, 2000). Thus COX-2 inhibitors may be useful for the
treatment of human malignancies with COX-2 and PGE2 over-
expression.
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Interferon-induced protein of 10 kDa (IP-10) induces antitu-
mor immune responses in synergy with interleukin-12 (Narvaiza
et al, 2000). Tumor cells can produce IP-10 in response to IFN-g
released by tumor-surrounding lymphocytes (Bukowski et al,
1999). The tumor-derived IP-10 chemoattracts activated CD4þ
T helper 1 cells, which promote tumor killing by natural killer
cells and macrophages or induce dendritic cells to prime cyto-
toxic T cells (Hung et al, 1998; Lanzavecchia, 1998; Narvaiza et al,
2000). In addition, IP-10 inhibits tumor angiogenesis (Arenberg
et al, 1996). The induction of IP-10 production in tumor cells
themselves is thus therapeutically useful for malignancy. A recent
study reported that exogenous PGE2 inhibited IP-10 secretion in
macrophages via cAMP (Kuroda et al, 2001); however, the precise
mechanism for the inhibition is not de¢ned. Besides it has not
been examined if tumor-derived PGE2 may suppress IP-10 pro-
duction in tumor cells themselves or if COX-2 inhibitor may
restore their IP-10 production by preventing PGE2 production.
In this study, we investigated the in vitro e¡ect of a selec-
tive COX-2 inhibitor, N-(2-cyclohexyloxyloxy-4-nitrophenyl)-
methanesulfonamide (NS398), on IFN-g-induced IP-10 produc-
tion in human epidermoid carcinoma A431. We found that
NS398 enhanced IP-10 production and exogenous PGE2 reversed
the enhancement. We further analyzed the mechanism for the
suppression by PGE2 of IFN-g-induced IP-10 production.
MATERIALS AND METHODS
Reagents 1,2-bis(2-aminophenoxy)ethane-N,N,N 0,N 0-tetraacetic acid
acetoxymethyl ester (BAPTA-AM), NS398, 5-(4-chlorophenyl)-1-(4-
methoxyphenyl)-3-tri£uoromethylpyrazole (SC560), 1-[6-((17b-3-methoxy-
estra-1,3,5(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione (U73122), N-
[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide (H-89),
and 9-(tetrahydro-20 -£uryl)adenine (SQ22536) were obtained from
Calbiochem (La Jolla, CA). PGE2, 17-phenyl trinor PGE2, and butaprost
were from Cayman Chemicals (Ann Arbor, MI). AH23848B was from
Funakoshi Pharmaceuticals (Tokyo, Japan). Recombinant human IFN-g
was purchased from R&D Systems (Minneapolis, MN). Antibodies against
COX-1, COX-2, b-actin, phosphotyrosine (PY20), signal transducer and
activator of transcription 1a (STAT1a p91, 48 kDa IFN-stimulated response
element (ISRE) binding protein (p48), Janus tyrosine kinase 1 (Jak1), and
Jak2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell line Human epidermoid carcinoma A431 was purchased from
Dainippon Pharmaceuticals (Osaka, Japan), and was cultured in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) (Gibco-BRL, Grand
Island, NY) supplemented with 10% fetal bovine serum (Gibco-BRL),
1% nonessential amino acids, 1 mM sodium pyruvate (ICN Biomedicals,
Aurora, OH), 100 U per ml penicillin G, and 100 mg per ml streptomycin
(Gibco-BRL).
Measurement of IP-10 secretion A431 cells (5104 per well) were
seeded in triplicate into 24-well plates, adhered overnight, washed, and
then incubated with serum-free DMEM for 24 h. The cells were
preincubated with NS398 for 2 h, and then incubated with PGE2 or
several PGE2 analogs for 10 min and ¢nally with 10 ng per ml IFN-g for
another 24 h. In some experiments, various signal inhibitors or EP4
antagonist AH23848B were added 10 min prior to the addition of PGE2.
The culture supernatants were assayed for IP-10 by enzyme-linked
immunosorbent assay (ELISA) (HyCult Biotechnology, Uden, The
Netherlands) according to the manufacturer’s instruction. The sensitivity
of the assay was 20 pg per ml.
Reverse transcription polymerase chain reaction (RT-PCR) A431
cells were harvested from subcon£uent culture or after incubation with
IFN-g for 3 h in the presence or absence of NS398 or PGE2 as above. The
cellular mRNA was extracted using an mRNA puri¢cation kit
(Pharmacia, Uppsala, Sweden) according to the manufacturer’s
instruction. cDNAwas made from RNA samples as described previously
(Tjandrawinata et al, 1997). Primer sequences for COX-1, COX-2, IP-10,
EP1, EP2, EP3, EP4, and b-actin were as described previously
(Mukhopadhyay et al, 1997; Boorsma et al, 1998; Kanda and Watanabe,
2001; Yoshida et al, 2001). PCRwas performed by one denaturing cycle of
951C for 3 min, 35 cycles of denaturation at 951C for 30 s, annealing at
581C for 30 s, extension at 721C for 30 s, and a ¢nal extension at 721C
for 3 min. The PCR products were analyzed by electrophoresis on 2.5%
agarose gels and stained with ethidium bromide, viewed by ultraviolet
light, and photographed. Densitometric analysis was performed by
scanning the bands into Photoshop and performing densitometry with
NIH Image Software. Results are expressed as the intensity ratio relative
to that of b-actin product.
Plasmids and transfections The ¢re£y luciferase reporter plasmids
driven by human IP-10 promoter (^525/þ 97 bp relative to the
transcriptional start site) were constructed by PCR and insertion into
pGL3 basic vector (Promega, Madison, WI) as described previously
(Majumder et al, 1998). Site-speci¢c mutation in ISRE and two nuclear
factor-kB (NF-kB) binding sites of the human IP-10 promoter were
created by PCR as described previously (Ohmori and Hamilton, 1993).
p3xISRE-SV-luc was constructed by inserting three copies of ISRE (50 -
CGCTTTGGAAAGTGAAACCTACCTC-30 with consensus sequence
underlined) from human IP-10 promoter in front of heterologous
minimal SV40 promoter upstream of ¢re£y luciferase reporter as
described previously (Ohmori and Hamilton, 1993; Ohmori et al, 1994).
Transient transfection was performed using Lipofectamine Plus reagent
(Gibco-BRL) according to the manufacturer’s protocol. Brie£y, A431 cells
were plated in six-well plates, grown to about 80% con£uence, and then
serum-deprived for 24 h. The cells were incubated with 1.8 mg of luciferase
construct and 0.2 mg of Rous sarcoma virus b-galactosidase vector per well
in a mixture of serum-free DMEM, Plus reagent, and Lipofectamine for 5
h, then washed, and incubated in serum-free DMEM for 18 h. Cells were
pretreated with NS398 for 2 h and then incubated with PGE2 or several
PGE2 analogs for 10 min, and ¢nally with IFN-g for another 6 h. In some
experiments, various signal inhibitors or AH23848B 20 mMwere added 10
min prior to the addition of PGE2. The cells were lyzed and luciferase
activities were quanti¢ed using a luciferase assay system (Promega). The
same cell extracts were assayed for b-galactosidase activity using
chemiluminescent Galacto-Light kit (Tropix, Bedford, MA). The results
obtained in each transfection were normalized for b-galactosidase activity
and expressed as relative luciferase activity.
Electrophoretic mobility shift assay The probe used was annealed
double-stranded DNA containing ISRE (sequence described above) from
the human IP-10 promoter. The probe was labeled by [32P]dCTP with
Klenow DNA polymerase. For gel-shift assays, 2^5 mg of nuclear
protein extracts were incubated at room temperature for 5 min with a
mixture containing 6 mM HEPES (pH 7.9), 0.4 mM ethylenediamine
tetraacetic acid (EDTA), 125 mM KCl, 10% glycerol, 0.05 mg per ml
poly(dI-dC), 1 mM dithiothreitol, 2.5 mM sodium pyrophosphate, 1 mM
b-glycerophosphate, 1 mM Na3VO4, 10 mM NaF, 50 mg per ml aprotinin,
and 50 mg per ml leupeptin. Approximately 1 ng labeled probe was added
and the reactions were incubated at room temperature for another 20 min.
In antibody supershift experiments, the nuclear extracts were preincubated
with various antibodies on ice for 30 min before the addition of the probe.
Reactions were then fractionated on a nondenaturing 5% polyacrylamide
gel in 0.5TBE. The gels were dried and visualized with phosphorimager
(Molecular Dynamics, Sunnyvale, CA).
Western blot analysis A431 cells from subcon£uent culture were
lyzed in a bu¡er containing 20 mM Tris^HCl (pH 7.5), 150 mM NaCl,
1 mM ethyleneglycol-bis(b-aminoethyl ether)-N,N,N0,N0-tetraacetic acid
(EGTA), 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM
b-glycerophosphate, 1 mM Na3VO4, 10 mM NaF, 50 mg per ml aprotinin,
and 50 mg per ml leupeptin, and centrifuged at 14,000 rpm for 10 min.
Protein concentration in the supernatant was determined by Bio-Rad DC
reagent (Bio-Rad Laboratories, Hercules, CA). ForWestern analysis, 20 mg
of proteins were resolved on a 10% sodium dodecyl sulfate (SDS)
polyacrylamide gel. The proteins were transferred to a nitrocellulose
membrane, and then blocked in 5% nonfat dry milk TBST (10 mM Tris,
pH 8.0, 150 mM NaCl, 0.05% Tween-20) for 1 h. The membrane was
incubated with anti-COX-2, anti-COX-1, or anti-b-actin antibodies for
2^3 h, and with horseradish-peroxidase-conjugated rabbit antigoat IgG
for 1 h, and was then developed by the enhanced chemiluminescence
system (Amersham, Arlington Heights, IL).
Analysis of STAT1a and Jak1/Jak2 phosphorylation The phosphoryla-
tion status of Jak1/Jak2 and STAT1a was assessed by immunoprecipitation
followed by immunoblotting as described previously (Delgado and Ganea,
2000). Cells were lyzed in ice-cold immunoprecipitation bu¡er (50 mMTris
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 20 mM b-glycerol
phosphate, 1 mM phenylmethylsulfonyl £uoride, 1 mg per ml leupeptin, 2
mg per ml aprotinin, 1 mg per ml pepstatin, 1% Nonidet p-40, 0.25%
deoxycholate, and 0.1% SDS). STAT1a and Jak1/Jak2 molecules were
immunoprecipitated by incubation with 10 mg per ml of the respective
antibodies. The immune complexes were captured on protein G-Sepharose
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beads (Pharmacia, Piscataway, NJ) for 1 h at 41C. Precipitated proteins were
washed by immunoprecipitation bu¡er and were separated by SDS
polyacrylamide gel electrophoresis and transferred to a nitrocellulose
membrane. The membrane was blocked and incubated with 1 mg per ml of
antiphosphotyrosine antibody (PY20), and then incubated with horseradish-
peroxidase-conjugated goat antimouse IgG and developed. Following the
analysis of phosphorylated molecules, the blots were stripped and reprobed
with antibodies against the respective proteins as described above.
PGE2 assay 510
4 per ml of A431 cells were plated in 24-well plates
and adhered overnight, washed, and serum-deprived as described above.
The cells were pretreated with serum-free DMEM alone or with NS398
or SC560 for 2 h and washed, and then 20 mM arachidonic acid (Sigma)
was added and the cells were cultured in the presence or absence of NS398
or SC560 in serum-free DMEM. After 1 h, PGE2 levels of the supernatants
were measured by ELISA (Cayman) according to the manufacturer’s
instruction. The sensitivity of the assay was 10 pg per ml. At the end of
the culture the number of cells was counted, and the results are expressed
as ng per 105 cells.
Measurement of cAMP amount A431 cells were plated at 5104 cells
per well in 24-well plates, adhered overnight, and then serum-deprived
for 24 h. They were pretreated with NS398 for 2 h, and then incubated
with PGE2 or PGE2 analogs for 10 min. The cells were lyzed with acetate
bu¡er (pH 5.8) containing 0.25% dodecyltrimethylammonium bromide.
The cAMP amount in the lysate was measured with an ELISA kit
(Amersham) according to the manufacturer’s instruction. The sensitivity
of the assay was 12 fmol per assay well. The intracellular cAMP level was
presented as pmol per 106 cells.
Assays of PKA A431 cells preincubated with NS398 were incubated
with PGE2 or PGE2 analogs for 10 min as described above. The cells were
lyzed in the bu¡er containing 20 mM Tris^HCl (pH 7.4), 1 mM EDTA, 1
mg per ml aprotinin, 1 mg per ml pepstatin, 1 mg per ml leupeptin, 15 mM
benzamidine, and 3.75 mM b-mercaptoethanol. The cell lysate was assayed
for the activity of PKA using an ELISA kit (Medical and Biological
Laboratories, Nagoya, Japan) by examining the phosphorylation of plate-
bound peptide substrate in the presence or absence of 2 mM cAMP
for 10 min at room temperature. The plates were sequentially incubated
with biotinylated antibody to the phosphorylated substrate, peroxidase-
conjugated streptavidin, o-phenylenediamine, and then the optical density
at 492 nm was read. The net optical density was calculated by subtracting
the optical density in the presence of speci¢c PKA inhibitor KT-5720
(Calbiochem) 1 mM from the total optical density. The PKA activity was
expressed as an activity ratio, which is de¢ned as the net optical density in
the absence of exogenous cAMP divided by the net optical density in the
presence of cAMP.
RESULTS
COX-1 and COX-2 expression, PGE2 production, and PGE2
receptor expression in A431 As examined by RT-PCR or
Western blotting (Fig 1a), the mRNAs and proteins for both
COX-1 and COX-2 were constitutively expressed in A431
though the level of COX-1 expression, as examined by relative
intensity, was slightly higher than that of COX-2: 1.8-fold and
1.2-fold higher by RT-PCR and Western blotting, respectively.
We then analyzed the contribution of COX-1 or COX-2 to the
PGE2 production.The constitutive PGE2 production in A431was
inhibited by 10 mM of selective COX-2 inhibitor NS398 (COX-1
IC504100 mM; COX-2 IC50¼3.8 mM; Futaki et al, 1994) by 95%
whereas the percentage inhibition by 0.1 mM of selective COX-1
inhibitor SC560 (COX-1 IC50¼ 0.009 mM; COX-2 IC50¼ 6.3
mM; Smith et al, 1998) was only 6% (Fig 1b). An increased
concentration of SC560, which may inhibit COX-2, was not
used. Thus the constitutive PGE2 production in A431 was
mainly dependent on COX-2. We then analyzed the mRNA
expression for four subtypes of PGE2 receptors, EP1, EP2, EP3,
and EP4, in A431. A431 expressed EP1, EP3, and EP4 mRNAs
but did not that of EP2 (Fig 1c). The order of expression level
was EP44EP14EP3; the band intensity normalized for that of
b-actin was 0.61, 0.32, and 0.13, respectively. It is thus indicated
that A431-derived PGE2 synthesized via COX-2 may act on
A431 cells themselves via EP1, EP3, or EP4.
The enhancement by NS398 of IFN-c-induced IP-10
secretion in A431, and the reversal by exogenous PGE2 To
know if A431-derived PGE2, which is produced via COX-2, may
suppress the IP-10 production in A431, we examined if COX-2
inhibitor NS398 may enhance the IP-10 secretion in A431, and if
exogenous PGE2 may reverse the enhancement. The constitutive
IP-10 secretion with medium alone was minimal in A431
(mean7SEM 5176 pg per ml, n¼ 5), and IFN-g dose-
dependently enhanced the IP-10 secretion: 203722 pg per ml by
IFN-g 1 ng per ml, 10807112 pg per ml by IFN-g 10 ng per ml,
35237321 pg per ml by IFN-g 100 ng per ml; more than 100 ng
per ml of IFN-g did not further increase the IP-10 secretion.
NS398 alone did not alter the IP-10 secretion; however, it
increased IP-10 secretion induced by suboptimal concentrations
of IFN-g (1 and 10 ng per ml) (Fig 2a). IP-10 secretion induced
by IFN-g 1 or 10 ng per ml was potentiated by NS398 10 mM 2.6-
fold or 2.1-fold of controls, respectively. On the other hand,
NS398 did not further enhance the IP-10 secretion induced
by a saturating concentration of IFN-g (100 ng per ml). Thus
NS398 increased IP-10 secretion in synergy with suboptimal
concentrations of IFN-g. In contrast, selective COX-1 inhibitor
SC560 did not alter the constitutive or IFN-g-induced IP-10
secretion. Thus the enhancement of IP-10 secretion by COX
inhibitors paralleled their inhibition of PGE2 production
(Fig 1b). Exogenous PGE2 reversed the enhancement by NS398
of IFN-g-induced IP-10 secretion (Fig 2b), indicating that the
enhancement by NS398 was mediated via preventing PGE2
production, and that PGE2 produced via COX-2 in A431 may
Figure1. The COX-1/COX-2 mRNA and protein expression (a),
PGE2 synthetic activity (b), and mRNA expression for PGE2 recep-
tor subtypes (c) in A431 cells. (a), (c) The mRNA expression of subcon-
£uent A431 cells was analyzed by RT-PCR (a, upper panel, and c). The
protein expression was analyzed byWestern blotting (a, lower panel). The re-
sults shown in the ¢gure are representative of ¢ve separate experiments. (b)
A431 cells were pretreated with NS398 or SC560 at the indicated concentra-
tions for 2 h and incubated with 20 mM arachidonic acid for 1 h; then the
supernatant PGE2 levels were measured.Values are mean7SEM of ¢ve se-
parate experiments. npo0.05 versus control cultures with medium alone, by
one-way anova with Sche¡e’s multiple comparison test.
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suppress IFN-g-induced IP-10 secretion.We then analyzed which
of the receptors may be involved in the PGE2-induced inhibition
of IP-10 secretion, using receptor agonists or antagonists. EP1 and
EP3 agonist 17 phenyl trinor PGE2 or EP2 agonist butaprost did
not reverse the enhancement by NS398 of IFN-g-induced IP-10
secretion (Fig 2b), indicating that EP1, EP2, or EP3 may not be
involved in the inhibition by PGE2 of IP-10 production. On the
other hand, the PGE2-induced inhibition of IP-10 secretion was
counteracted by EP4 antagonist AH23848B, indicating that the
e¡ect of PGE2 may be mediated via EP4. These results suggest
that A431-derived PGE2, which is synthesized via COX-2, may
latently suppress IFN-g-induced IP-10 secretion via EP4 in A431
cells. We then examined if NS398 may enhance IP-10 mRNA
expression induced by suboptimal concentrations of IFN-g in
A431 and if exogenous PGE2 may reverse the enhancement.
Enhancement by NS398 of IFN-c-induced IP-10 mRNA
expression, and its reversal by exogenous PGE2 Though
NS398 alone did not alter IP-10 mRNA levels in unstimulated
A431 cells, NS398 enhanced IP-10 mRNA expression induced
by 10 ng per ml of IFN-g 2.5-fold (Fig 3). The e¡ect of NS398
was reversed by exogenous PGE2 but not by butaprost or 17
phenyl trinor PGE2 (data not shown), and the e¡ect of PGE2
was counteracted by EP4 antagonist AH23848B. On the other
hand, SC560 did not enhance the IFN-g-induced IP-10 mRNA
expression. IFN-g 100 ng per ml increased IP-10 mRNA level
13.5-fold of controls, which was not further enhanced by NS398
(data not shown). Thus the results on IP-10 mRNA expression
paralleled those for IP-10 secretion (Fig 2). The results suggest
that NS398-induced stimulation and PGE2-induced inhibition
of IFN-g-induced IP-10 synthesis occurred at pretranslational
level, and that the e¡ect of PGE2 may be mediated via EP4.We
then examined whether NS398 may enhance IP-10 promoter
activity induced by IFN-g in A431 and whether exogenous
PGE2 may reverse the enhancement by NS398.
Enhancement by NS398 of IFN-c-induced IP-10 promoter
activation and its reversal by exogenous PGE2 We
transiently transfected human IP-10 promoter^luciferase reporter
constructs into A431 cells, and the promoter activity was assessed
by the relative luciferase activity of the cell lysate. IFN-g 10 ng
per ml increased wild-type IP-10 promoter activity 11.5-fold of
controls (Fig 4b, uppermost ¢ve columns), and NS398 further
enhanced the response to IFN-g 2.3-fold, although NS398 alone
did not enhance the constitutive IP-10 promoter activity (data not
shown). Exogenous PGE2 reversed the enhancement by NS398
but butaprost and 17 phenyl trinor PGE2 did not (data not
shown), and the e¡ect of PGE2 was counteracted byAH23848B.
IFN-g 100 ng per ml increased the wild-type IP-10 promoter
activity 31.2-fold of controls, which was not further enhanced
by NS398 (data not shown). SC560 did not alter constitutive or
IFN-g-induced IP-10 promoter activity (data not shown). These
results suggest that PGE2 produced via COX-2 in A431 may
suppress IP-10 promoter activation by suboptimal concentrations
of IFN-g, and that the suppression may be mediated via EP4.The
Figure 2. The enhancement by COX-2 inhibitor of IFN-c-induced
IP-10 secretion (a) and its reversal by exogenous PGE2 (b). (a) A431
cells were preincubated with 10 mM NS398 or 0.1 mM SC560 for 2 h, and
then incubated with IFN-g at the indicated concentrations. After 24 h, the
culture supernatants were assayed for IP-10.Values are mean7SEM of ¢ve
separate experiments. npo0.05 versus control cultures without COX inhi-
bitors, by one-way ANOVA with Sche¡e’s multiple comparison test. (b)
A431 cells were preincubated for 2 h with 10 mM NS398 (NS), then incu-
bated with 0.1 mM PGE2 (PG), 10 mM butaprost, or 10 mM17 phenyl trinor
PGE2 (17ptPG) for 10 min, and ¢nally with IFN-g 10 ng per ml for an-
other 24 h. The supernatants were assayed for IP-10. In some experiments,
20 mM AH23848B (AH) was added 10 min prior to the addition of PGE2.
Values are mean7SEM of ¢ve separate experiments. npo0.05 versus con-
trol values with medium alone; wpo0.05 versus values with IFN-g alone;
zpo0.05 versus values with IFN-g plus NS398; ypo0.05 versus values with
IFN-g plus NS398 plus PGE2, by one-wayANOVAwith Sche¡e’s multiple
comparison test.
Figure 3. The enhancement by COX-2 inhibitor of IFN-c-induced
IP-10 mRNA expression and its reversal by exogenous PGE2. A431
cells were preincubated for 2 h with 10 mM NS398 or 0.1 mM SC560,
washed, then incubated with 0.1 mM PGE2 for 10 min, and ¢nally with
IFN-g 10 ng per ml for another 3 h; then mRNA expression was analyzed.
In some experiments, 20 mM AH23848B was added 10 min prior to the
addition of PGE2.The intensity of the band for IP-10 was corrected to that
for b-actin. The lower panel shows the corrected intensities relative to those
in control cells cultured with medium alone (set as 1.0). The results shown
in the ¢gure are representative of ¢ve separate experiments.
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results also suggest that NS398 may restore the IP-10 promoter
induction by preventing PGE2 production.
It is known that IFN-g-induced IP-10 transcription requires
the cooperation of ISRE with at least one of the two NF-kB
sites on the IP-10 promoter (Ohmori and Hamilton, 1993;
Ohmori et al, 1997).We thus examined which of these elements
may be responsible for the enhancement by NS398 and the
inhibition by PGE2 of the IFN-g-induced IP-10 transcription,
using promoters with mutation in each element. The mutation
of ISRE completely abrogated the IFN-g-induced activation of
IP-10 promoter and the enhancement by NS398 or the
suppression by PGE2 of the response to IFN-g (Fig 4b, the second
¢ve columns), suggesting that ISRE is necessary for IFN-g-induced
promoter activation and may be involved in the enhancement by
NS398 and suppression by PGE2 of the response to IFN-g.When
either NF-kB2 (distal NF-kB site) or NF-kB1 (proximal NF-kB
site) was mutated, the basal promoter activity was reduced,
whereas the fold-induction by IFN-g and the enhancement by
NS398 and suppression by PGE2 of the response to IFN-g were
retained. This indicates that the two NF-kB sites may not be
involved in the enhancement by NS398 or suppression by PGE2
of the response to IFN-g.We then analyzed whether NS398 may
enhance the ISRE-dependent transcription induced by IFN-g in
A431, and whether PGE2 may reverse the enhancement.
Enhancement by NS398 of the IFN-c-induced transcription
from ISRE, and its reversal by exogenous PGE2 A431 cells
were transiently transfected with plasmids containing three
repeats of ISRE linked to the heterologous minimal SV40
promoter and luciferase reporter, and were preincubated with
NS398 and then incubated with IFN-g. The ISRE-dependent
transcriptional activity was evaluated by the relative luciferase
activity. The enhancerless SV40 promoter^luciferase vector
produced very low background luciferase activity, which was
not altered by IFN-g, NS398, or PGE2, either alone or in
combination (Fig 5, lower ¢ve columns). IFN-g increased the
ISRE-dependent transcriptional activity, and NS398 further
enhanced the response to IFN-g 2.1-fold (Fig 5, upper ¢ve
columns). The enhancement by NS398 was reversed by PGE2,
and the e¡ect of PGE2 was counteracted by AH23848B. IFN-g
100 ng per ml increased the transcriptional activity through
ISRE 30.3-fold of controls, which was not further enhanced by
NS398 (data not shown). SC560 did not alter the constitutive or
IFN-g-induced transcriptional activity through ISRE (data not
shown). These results suggest that PGE2 produced via COX-2 in
A431may suppress the ISRE-dependent transcription induced by
suboptimal concentrations of IFN-g, and that the suppression
may be mediated via EP4. The results also suggest that NS398
may restore the response to IFN-g by preventing PGE2
production. We then examined whether NS398 may enhance
the IFN-g-induced transcription factor binding to ISRE in
A431 cells, and whether exogenous PGE2 may reverse the
enhancement by NS398.
Enhancement by NS398 of the IFN-c-induced transcription
factor binding to ISRE, and its reversal by exogenous
PGE2 Nuclear extracts were obtained from A431 cells pre-
incubated with NS398 and incubated with IFN-g. An
electrophoretic mobility shift assay was performed using ISRE
probe. Incubation of A431 cells with 10 ng per ml IFN-g
induced the DNA^protein complex associated with the ISRE
probe (Fig 6, lane 3). The complex associated with the ISRE
probe was competed by 50-fold excess of unlabeled ISRE probe
Figure 4. The enhancement by COX-2 inhibitor of the IFN-c-in-
duced activities of wild-type or mutated IP-10 promoters and its
reversal by exogenous PGE2. (a) Schematic representation of human
IP-10 promoter. The locations of ISRE, NF-kB2, and NF-kB1 are shown
with their sequences, and substituted or deleted bases for mutation are in-
dicated.The nucleotide positions are relative to the transcriptional start site.
(b) A431 cells were transiently transfected with wild-type (WT) or mutated
human IP-10 promoter linked to luciferase reporter together with b-galac-
tosidase vector. The cells were preincubated with 10 mM NS398 (NS) for 2
h, then treated with 0.1 mM PGE2 (PG) for 10 min, and ¢nally with IFN-g
10 ng per ml for another 6 h. In some experiments, 20 mM AH23848B
(AH) was added 10 min prior to the addition of PGE2. Relative luciferase
activities normalized to b-galactosidase activities are shown. The data are
mean7SEM of four separate experiments.Values at right indicate the fold
induction versus basal promoter activity. npo0.05 versus control values;
zpo0.05 versus values with IFN-g alone; zpo0.05 versus values with IFN-
g plus NS398; ypo0.05 versus values with IFN-g plus NS398 plus PGE2, by
one-wayANOVAwith Sche¡e’s multiple comparison test.
Figure 5. The enhancement by COX-2 inhibitor of ISRE-depen-
dent transcription induced by IFN-c, and its reversal by PGE2.
A431 cells were transiently transfected with luciferase reporter plasmids
driven by ISRE linked to heterologous SV-40 minimal promoter, together
with b-galactosidase vector. The cells were preincubated with 10 mM
NS398 (NS) for 2 h, then treated with 0.1 mM PGE2 (PG) for 10 min, and
¢nally with IFN-g 10 ng per ml for another 6 h. In some experiments, 20
mMAH23848B (AH) was added 10 min prior to the addition of PGE2.The
results are shown as relative luciferase activities normalized for b-galactosi-
dase activities, and represent mean7SEM of four separate experiments.
Values at right indicate the fold induction versus basal activity. npo0.05 ver-
sus control values with medium alone; wpo0.05 versus values with IFN-g
alone; zpo0.05 versus values with IFN-g plus NS398; ypo0.05 versus values
with IFN-g plus NS398 plus PGE2, by one-way ANOVA with Sche¡e’s
multiple comparison test.
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(data not shown). NS398 alone did not induce the DNA^protein
complex with the ISRE probe (Fig 6, lane 2); however, it
increased the amount of the complex induced by 10 ng per ml
IFN-g (Fig 6, lane 4). The antibodies against STAT1a and 48
kDa ISRE binding protein (p48) supershifted the NS398 plus
IFN-g-induced complex with the ISRE probe (Fig 6, lanes 7, 8),
indicating the presence of STAT1a and p48 in the complex.
The antibody against IFN regulatory factor 1 did not alter the
migration of the complex with ISRE (data not shown).
Exogenous PGE2 reversed the enhancement by NS398 of the
complex formation with the ISRE probe, and AH23848B
counteracted the suppression by PGE2 (Fig 6, lanes 5, 6). The
amount of the complex with the ISRE probe was increased by
increasing IFN-g concentrations up to 100 ng per ml, which was
not further enhanced by NS398 (data not shown). SC560 did not
alter the amount of the complex induced by IFN-g (data not
shown). These results suggest that PGE2 produced via COX-2 in
A431 may suppress STAT1a/p48 binding to ISRE induced by
suboptimal concentrations of IFN-g, and that the suppression
may be mediated via EP4. The results also suggest that NS398
may restore the STAT1a/p48 binding by preventing PGE2
production.
Enhancement by NS398 of IFN-c-induced tyrosine
phosphorylation of STAT1a, Jak1, and Jak2, and its reversal
by exogenous PGE2 IFN-g-induced activation of STAT1a
is mediated by Jak1 and Jak2 (Delgado and Ganea, 2000). Up-
on IFN-g binding, cell surface IFN-g receptor dimerizes, which
allows the receptor-associated Jak1 and Jak2 to autophosphorylate
on tyrosine residues and interact with each other. The activated
Jak1 and Jak2 tyrosine-phosphorylate the intracellular domains
of the receptors, which recruits STAT1a to the phosphotyrosine
residues of the receptor through the interaction with Src
homology 2 domain of STAT1a. The receptor-associated
STAT1a is tyrosine-phosphorylated by the activated Jak1 and
Jak2, which induces STAT1a dimerization and association
with p48. The activated STAT1a homodimers/p48 complex
translocates to the nucleus and binds to ISRE on IP-10 gene
(Bluyssen et al, 1995). Thus the enhancement by NS398 or the
suppression by PGE2 of IFN-g-induced STAT1a activation
indicates that NS398 may enhance the IFN-g-induced tyrosine
phosphorylation of STAT1a, Jak1, or Jak2, and that exogenous
PGE2 may reverse the enhancement by NS398. We thus
examined the e¡ects of NS398 or PGE2 on the IFN-g-induced
tyrosine phosphorylation of these molecules. The incubation
with IFN-g 10 ng per ml for 10 min induced tyrosine
phosphorylation of STAT1a, Jak1, and Jak2 in A431 cells (Fig 7,
upper panel, lane 2). NS398 enhanced the IFN-g-induced tyrosine
phosphorylation of STAT1a, Jak1, and Jak2 (Fig 7, upper panel,
lane 3), and the enhancement by NS398 was reversed by
exogenous PGE2; the suppression by PGE2 was counteracted by
AH23848B (Fig 7, upper panel, lanes 4, 5). The total amount of
STAT1a, Jak1, or Jak2 in the immunoprecipitates was not altered
by IFN-g, NS398, or PGE2, either alone or in combination
(Fig 7, lower panel). The tyrosine phosphorylation of STAT1a,
Jak1, and Jak2 was enhanced by increasing IFN-g concentrations
up to 100 ng per ml, which was not further enhanced by NS398
(data not shown). SC560 did not enhance the IFN-g-induced
tyrosine phosphorylation of STAT1a, Jak1, and Jak2 (data not
shown). These results suggest that PGE2 produced via COX-2 in
A431 may interact with the cell surface EP4 and suppress the
Jak1,2/STAT1a signaling pathway induced by suboptimal concentra-
tions of IFN-g. The results also suggest that NS398 may restore the
IFN-g-induced activation of Jak1,2/STAT1a by preventing PGE2
production.
PGE2-induced signaling pathways responsible for the
inhibition of IFN-c-induced Jak1,2/STAT1a activation and
IP-10 production PGE2 binding to EP2 or EP4 stimulates
AC via Gs and increases intracellular cAMP (Ashby, 1998), which
activates cAMP-dependent protein kinase (PKA). On the other
hand, PGE2 binding to EP3 inhibits AC via G-protein
inhibitory subunit (Gi) (Schmid et al, 1995) or activates
phospholipase C and generates inositol 1,4,5 triphosphate, which
induces Ca2þ mobilization from intracellular stores (Asboth et al,
1997/98). PGE2 binding to EP1 induces Ca
2þ in£ux through
the membrane Ca2þ channel (Asboth et al, 1997/98). We thus
Figure 6. The enhancement by COX-2 inhibitor of IFN-c-induced
transcription factor binding to ISRE, and its reversal by exogenous
PGE2. A431 cells were preincubated with 10 mM NS398 for 2 h, then trea-
ted with 0.1 mM PGE2 for 10 min, and ¢nally with IFN-g 10 ng per ml for
another 30 min. In some experiments, 20 mM AH23848B was added 10
min prior to the addition of PGE2. Nuclear extracts were incubated with
32P-labeled oligonucleotides containing ISRE from human IP-10 promo-
ter. In supershift assays, antibodies against transcription factors were incu-
bated for 30 min before the addition of the probe. Arrows indicate the
supershifted complexes. The results shown in the ¢gure are representative
of four separate experiments.
Figure 7. The enhancement by COX-2 inhibitor of STAT1a (a), Jak1 (b), or Jak2 (c) tyrosine phosphorylation induced by IFN-c, and the
reversal by exogenous PGE2 of the enhancement. A431 cells were preincubated with or without 10 mM NS398 (NS) for 2 h, then treated with 0.1
mM PGE2 for 10 min, and ¢nally with IFN-g 10 ng per ml for another 10 min. In some experiments, 20 mMAH23848B (AH) was added 10 min prior to the
addition of PGE2. Cell lysates were immunoprecipitated with anti-STAT1a, Jak1, or Jak2 antibodies followed by immunoblotting with antiphosphotyrosine
antibody (upper panels). The blots were reprobed with anti-STAT1a, Jak1, or Jak2 antibodies, respectively (lower panels). The results shown in the ¢gure are
representative of ¢ve separate experiments.
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examined whether the cAMP/PKA pathway may be involved in
the suppression by PGE2 of IFN-g-induced IP-10 synthesis. A431
cells were pretreated with NS398, treated with several signal
inhibitors, and then treated with PGE2 prior to the addition of
IFN-g. AC inhibitor SQ22536 and PKA inhibitor H-89
counteracted the suppression by PGE2 of NS398 plus IFN-g-
induced IP-10 secretion (Fig 8a), IP-10 mRNA expression
(Fig 8c), and IP-10 promoter activation (Fig 8b), whereas these
were not counteracted by phospholipase C inhibitor U73122,
intracellular Ca2þ chelator BAPTA-AM, or extracellular Ca2þ
chelator EGTA. This suggests that the cAMP/PKA signaling
pathway may be responsible for the suppression by PGE2 of IP-
10 synthesis whereas phospholipase C or Ca2þ signal may not
be involved. As the suppression by PGE2 of Jak1,2/STAT1a
activation was responsible for the inhibition of IP-10 synthesis,
we analyzed whether the cAMP/PKA pathway may also be
involved in the suppression by PGE2 of Jak1,2/STAT1a
activation. SQ22536 and H-89 counteracted the suppression by
PGE2 of ISRE-dependent transcription induced by IFN-g plus
NS398 in A431 cells, whereas it was not counteracted by
U73122, BAPTA-AM, or EGTA (Fig 9a), which paralleled the
results for IP-10 synthesis (Fig 8). SQ22536 and H-89 did
counteract the suppression by PGE2 of DNA^protein complex
formation with the ISRE probe and of tyrosine phosphorylation
of STAT1a, Jak1, and Jak2 (Fig 9b, c, lanes 5, 6), but U73122,
BAPTA-AM, and EGTA did not (Fig 9b, c, lanes 7, 8, 9). The
total amount of STAT1a, Jak1, or Jak2 in the immuno-
precipitates was not altered by IFN-g, NS398, PGE2 signal
inhibitors alone or in combination (Fig 9c, lower panels). These
results suggest that the cAMP/PKA pathway may be responsible
for the inhibition by PGE2 of the activation of Jak1,2/STAT1a in
A431 cells but phospholipase C or Ca2þ signal may not.
PGE2-induced cAMP signal and PKA activation We ¢nally
examined if PGE2 may increase intracellular cAMP and activate
PKA in A431 cells. A431 cells were preincubated with NS398
prior to the addition of PGE2. A 10 min incubation with PGE2
in the presence of NS398 increased the intracellular cAMP
level 14.4 -fold of controls and enhanced PKA activity in
parallel (Fig 10a, b). AH23848B counteracted the PGE2-induced
increases of cAMP and PKA activity. Butaprost or 17 phenyl
trinor PGE2 did not alter cAMP level or PKA activity in A431.
These results suggest that PGE2 may stimulate AC via EP4, but
not via EP1, EP2, or EP3, and generate cAMP signal and
resultantly activate PKA in A431.
DISCUSSION
This study demonstrated that the selective COX-2 inhibitor
NS398 enhanced IFN-g-induced IP-10 production in human epi-
dermoid carcinoma A431, and that the enhancement was reversed
by exogenous PGE2.This suggests that PGE2 produced via COX-
2 in A431may latently suppress the IFN-g-induced IP-10 produc-
tion. PGE2 produced by A431 cells themselves may transiently
reach extremely high concentrations at the cell surface, and thus
may be much more e¡ective for the suppression of IP-10 produc-
tion than exogenous PGE2. PGE2 may thus play an autocrone/
paracrine role in tumor cells for the escape from IP-10-induced
antitumor immunity. The suppression by PGE2 of IP-10 produc-
tion was mediated via EP4. Recent studies showed that EP4 ex-
pression was enhanced in murine skin squamous cell carcinoma
(Thompson et al, 2001), and that PGE2 synthesized by tumor cells
may potentiate their own EP4 expression (Sales et al, 2002). PGE2
also promotes the expression of its own synthesizing enzyme
Figure 8. The inhibition by several signal inhibitors of PGE2-induced suppression of IP-10 secretion (a), IP-10 promoter activity (b), and IP-
10 mRNA expression (c) induced by IFN-c plus COX-2 inhibitor. (a), (c) A431 cells were preincubated with 10 mM NS398 (NS) for 2 h, then treated
with 200 mM SQ22536, 1 mMH-89, 1 mMU73122, 50 mM BAPTA-AM, or 2 mM EGTA for 10 min, then incubated with 0.1 mM PGE2 (PG) for 10 min, and
¢nally with IFN-g 10 ng per ml. IP-10 secretion was analyzed after 24 h, and mRNAwas extracted after 3 h. (b) A431 cells were transiently transfected with
human IP-10 promoter linked to luciferase reporter plasmid, and incubated as above. After 6 h, luciferase activities of the cell lysates were analyzed and were
normalized for b-galactosidase activities. In (a) and (b), values are mean7SEM of ¢ve separate experiments. npo0.05 versus control values with medium
alone; wpo0.05 versus values with IFN-g alone; zpo0.05 versus values with IFN-g plus NS398; ypo0.05 versus cultures with IFN-g plus NS398 plus PGE2,
by one-wayANOVAwith Sche¡e’s multiple comparison test. The results shown in (c) are representative of ¢ve separate experiments.
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COX-2 in A431 (Kanda andWatanabe, 2002).Thus PGE2 synthe-
sized by tumor cells may promote its own synthesis and respon-
siveness to itself in tumor cells, and thus amplify its function to
suppress IP-10 production.
A431 expresses EP3, which couples to the inhibition of AC, in
addition to EP4 coupled to AC stimulation; however, PGE2
greatly (14.4-fold of controls) increased cAMP level in A431
(Fig 10). This indicates that the stimulation of AC via EP4 may
overwhelm its inhibition via EP3. The total e¡ect of PGE2 on
AC activity may depend on the relative expression of EP4 versus
EP3; at least in mRNA expression, EP4 level was higher than
that of EP3 in A431 (Fig 1). The total e¡ect of PGE2 on AC
may also be in£uenced by Gi or Gs coupling e⁄ciency of EP3
or EP4, respectively. At least six splicing variants of human EP3
have been identi¢ed (Schmid et al, 1995), and they di¡er in the
structure of intracellular carboxyl terminal domains, which
may be an important determinant of Gi coupling e⁄ciency (Ash-
by, 1998). EP3 isoform(s) in A431 may not be e⁄ciently coupled
to Gi. The interaction of PGE2 receptors with G-proteins may
also be in£uenced by the amounts or localization of G-proteins
on plasma membranes or constrained by cytoskeletons like
microtubules (Nishigaki et al, 1998). Further studies should iden-
tify the amounts, isoforms, or G-protein coupling status of EP3
and EP4 in A431.
cAMP induced by PGE2 may bind to the regulatory subunits
of PKA and release free, active catalytic subunits. The active PKA
catalystsmayinhibittheIFN-g-inducedactivationof Jak1,2/STAT1a
signaling pathway, and resultantly inhibit IP-10 transcription.
Previous studies reported that cAMP inhibited STAT1 activation
by multiple mechanisms (Bouchard et al, 1994; David et al, 1996;
Ivashkiv et al, 1996; Catalan et al, 1997; Lee and Rikihisa, 1998;
Meloche et al, 2000; Rocchi et al, 2000): (i) PKA may suppress
the synthesis of STAT1 (Ivashkiv et al, 1996); (ii) PKA may sup-
press the synthesis of Jak1 or Jak2 (Meloche et al, 2000); (iii)
PKA may directly phosphorylate Jak1 or Jak2 on serine residues,
which prevents their phosphorylation on tyrosine and thus re-
duces their tyrosine kinase activities (Meloche et al, 2000); (iv)
PKA may stimulate the activity of protein tyrosine phosphatase,
which inactivates Jak1 or Jak2 (Bouchard et al, 1994; Catlan et al,
1997; Meloche et al, 2000; Rocchi et al, 2000). Among these, the
¢rst and second mechanisms are rather unlikely for PGE2 as the
PGE2-induced suppression of Jak1,2/STAT1a activation occurred
rapidly (within 10 min), and the amount of these molecules was
not altered by PGE2.The third mechanism is assumed for another
Jak family kinase,Tyk2; however, it is reported that Jak1 and Jak2
do not contain possible PKA recognition sites (Meloche et al,
2000). The fourth mechanism is most likely as PKA directly
phosphorylates tyrosine phosphatase SHPTP2 on serine, which
enhances its tyrosine phosphatase activity (Catlan et al, 1997).
cAMP-elevating agent also upregulates the tyrosine phosphatase
activity of protein tyrosine phosphatase SHPTP1 (Bouchard
et al, 1994), and SHPTP1 can be serine-phosphorylated by PKA
(Yin et al, 1997). Both SHPTP2 and SHPTP1 contain Src homol-
ogy 2 domains and can interact with Jak1 and Jak2 (David et al,
1995; Klingmuller et al, 1995;You et al, 1999). SHPTP2 is known to
inhibit IFN-g-induced tyrosine phosphorylation of Jak1 (You
et al, 1999). SHPTP1 is supposed to inhibit IFN-a/b-induced tyr-
osine phosphorylation of Jak1 and STAT1a (Klingmuller et al,
1995) and erythropoietin-induced Jak2 activation (You et al,
1999). It is thus plausible that PGE2 may suppress the IFN-g-in-
Figure 9. The inhibition by several signal inhibitors of the suppres-
sion by PGE2 of ISRE-dependent transcription (a), transcription
factor binding to ISRE (b), and STAT1a, Jak1, or Jak2 tyrosine
phosphorylation (c) induced by IFN-c plus NS398. (a) A431 cells were
transiently transfected with luciferase reporter vector driven by ISRE
linked to minimal SV40 promoter. Cells were preincubated with 10 mM
NS398 (NS) for 2 h and treated with 200 mM SQ22536, 1 mM H-89, 1
mM U73122, 50 mM BAPTA-AM, or 2 mM EGTA for 10 min, then incu-
bated with 0.1 mM PGE2 (PG) for 10 min, and ¢nally with IFN-g 10 ng per
ml. After 6 h, luciferase activities were analyzed and normalized for b-ga-
lactosidase activities. The data are mean7SEM of ¢ve separate experi-
ments. npo0.05 versus control values with medium alone; wpo0.05 versus
values with IFN-g alone; zpo0.05 versus values with IFN-g plus NS398;
ypo0.05 versus values with IFN-g plus NS398 plus PGE2, by one-way AN-
OVAwith Sche¡e’s multiple comparison test. (b), (c) A431 cells were incu-
bated as above. After 30 min, nuclear extracts were analyzed for
electrophoretic mobility shift assay using ISRE probe (b). Cell lysates were
obtained after 10 min, and immunoprecipitated with anti-STAT1a, Jak1, or
Jak2 antibodies followed by immunoblotting with antiphosphotyrosine
antibody (c, upper panels). The blots were also reprobed with anti-STAT1a,
Jak1, or Jak2 antibodies, respectively (c, lower panels). The results shown in
the ¢gure are representative of ¢ve separate experiments.
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Figure10. PGE2-induced increase of intracellular cAMP level (a)
and activation of PKA (b). A431 cells were preincubated with 10 mM
NS398 for 2 h, then incubated with 0.1 mM PGE2, 10 mM butaprost, or 10
mM17 phenyl trinor PGE2. After 10 min, intracellular cAMP concentration
and PKA activity were analyzed. The results are shown as mean7SEM of
¢ve separate experiments. n, po0.05 versus control values with medium
alone; w, po0.05 versus values with PGE2 alone, by one-wayANOVAwith
Sche¡e’s multiple comparison test.
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duced Jak1 or Jak2 activation by enhancing the tyrosine phospha-
tase activity of SHPTP1 or SHPTP2 via PKA in A431. Further
studies should elucidate the direct e¡ects of PGE2 on SHPTP1,
SHPTP2, or another protein tyrosine phosphatase that can inacti-
vate Jak1 or Jak2. Another possible mechanism is that activated
PKA may associate with and serine-phosphorylate IFN-g recep-
tor and thus change its conformation, which may prevent its di-
merization and the activation of Jak1/Jak2 associated with the
receptor. Further studies should de¢ne if PGE2 may modify the
association of PKAwith IFN-g receptor.
Though steady state mRNA and protein levels of COX-2
were rather lower than those of COX-1, the contribution of
COX-2 activity to the total PGE2 production was much higher
than that of COX-1 (Fig 1). This indicates that COX-2 enzymatic
activity may be selectively enhanced by post-translational modi-
¢cation. A previous study also reported that COX-2, but not
COX-1, in newborn pig cerebral endothelial cells was phos-
phorylated on tyrosine residues, and that the selective tyrosine
phosphorylation may promote the enzymatic activity of COX-2
(Parfenova et al, 1998). A similar mechanism for the selective
COX-2 activation is supposed in A431.
Our results in vitro indicate the in vivo autocrine/paracrine role
of PGE2 for the suppression of IP-10 production in tumor cells.
The results also suggest that COX-2 inhibitor NS398 may coun-
teract the suppressive e¡ect of endogenous PGE2 and restore the
IFN-g-induced IP-10 production, which may promote host anti-
tumor immunity and suppress tumor angiogenesis. As PGE2 it-
self enhances angiogenesis and also induces the production of
angiogenic factors such as vascular endothelial growth factor
(Sales et al, 2002), NS398 may suppress tumor angiogenesis by
dual mechanisms via inducing IP-10 and preventing PGE2 pro-
duction. Thus NS398 may be useful for the treatment of skin tu-
mors overexpressing COX-2. The combination of NS398 with
IFN-g may enhance the therapeutic e⁄cacy of IFN-g for malig-
nancy. The usage of selective COX-2 inhibitors for malignancy
may be more e¡ective and safe than that of dual COX inhibitors
such as indomethacin; COX-2 is less sensitive to indomethacin
than COX-1 and thus the inhibition of COX-2 requires a higher
dosage of indomethacin, which may induce gastric ulcers or ne-
phrotoxicity due to COX-1 inhibition (Smith and DeWitt, 1995).
As COX-2 expression is also enhanced in tumor-surrounding
macrophages or endothelial cells (Huang et al, 1998; Sales et al,
2001), we are now studying whether NS398 may enhance the
IFN-g-induced IP-10 production in macrophages or endothelial
cells in vitro and whether the enhancement may be reversed by
exogenous PGE2.
This work is supported in part by aid from KANAE Medical Research Foundation.
REFERENCES
Anastassiou ED, Paliogianni F, Balow JP, Yamada H, Boumpas T: Prostaglandin E2
and other cyclic AMP-elevating agents modulate IL-2 and IL-2Ra gene ex-
pression at multiple levels. J Immunol 148:2845^2852, 1992
Arenberg DA, Kunkel SL, Polverini PJ, et al: Interferon-g-inducible protein 10 (IP-
10) is an angiostatic factor that inhibits human non-small cell lung cancer
(NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184:981^992,
1996
Asboth G, Phaneuf S, Lopez Bernal AL: Prostaglandin E receptors in myometrial
cells. Acta Physiol Hung 85:39^50, 1997/98
Ashby B: Co-expression of prostaglandin receptors with opposite e¡ects. Biochem
Pharmacol 55:239^246, 1998
Bluyssen HA, Muza¡ar R,Vlieststra RJ, et al: Combinatorial association and abun-
dance of components of interferon-stimulated gene factor 3 dictate the selec-
tivity of interferon responses. Proc Natl Acad Sci USA 92:5645^5649, 1995
Boorsma DM, Flier J, Sampat S, et al: Chemokine IP-10 expression in cultured hu-
man keratinocytes. Arch Dermatol Res 290:335^341, 1998
Bouchard P, Zhao Z, Banville D, Dumas F, Fischer EH, Shen S-H: Phosphorylation
and identi¢cation of a major tyrosine phosphorylation site in protein tyrosine
phosphatase 1C. J Biol Chem 269:19585^19589, 1994
Bukowski RM, Rayman P, Molto L, et al: Interferon-g and CXC chemokine induc-
tion by interleukin 12 in renal cell carcinoma. Clin Cancer Res 5:2780^2789,
1999
Catalan RE, Gargiulo L, Martinez AM, Calcerrada MC, Liras A: Protein tyrosine
phosphatase activity modulation by endothelin-1 in rabbit platelets. FEBS Lett
400:280^284, 1997
David M, Chen HE, Goelz S, Larner AC, Neel BG: Di¡erential regulation of the
alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-contain-
ing tyrosine phosphatase SHPTP1. Mol Cell Biol 15:7050^7058, 1995
David M, Petricoin E III, Larner AC: Activation of protein kinase A inhibits inter-
feron induction of the Jak/Stat pathway in U266 cells. J Biol Chem 271:4585^
4588, 1996
Delgado M, Ganea D: Inhibition of IFN-g-induced Janus kinase-1-STAT1 activation
in macrophages by vasoactive intestinal peptide and pituitary adenylate cy-
clase-activating polypeptide. J Immunol 165:3051^3057, 2000
Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S: NS-398, a new
anti-in£ammatory agent, selectively inhibits prostaglandin G/H synthase/cy-
clooxygenase (COX-2) activity in vitro. Prostaglandins 47:55^59, 1994
Gallo O, Franchi A, Magnelli L, et al: Cyclooxygenase-2 pathway correlates with
VEGF expression in head and neck cancer. Implications for tumor angiogen-
esis and metastasis. Neoplasia 3:53^61, 2001
Huang M, Stolina M, Sharma S, et al: Non-small cell lung cancer cyclooxygenase-2-
dependent regulation of cytokine balance in lymphocytes and macrophages:
up-regulation of interleukin 10 and down-regulation of interleukin 12 produc-
tion. Cancer Res 58:1208^1216, 1998
Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The
central role of CD4þ T cells in the antitumor immune response. J Exp Med
188:2357^2368, 1998
Ivashkiv LB, Schmitt EM, Castro A: Inhibition of transcription factor Stat1 activity
in mononuclear cell cultures and T cells by the cyclic AMP signaling pathway.
J Immunol 157:1415^1421, 1996
Kanda N, Watanabe S: Regulatory roles of adenylate cyclase and cyclic nucleotide
phosphodiesterases 1 and 4 in interleukin-13 production by activated human T
cells. Biochem Pharmacol 62:495^507, 2001
Kanda N,Watanabe S: Ketoconazole suppresses prostaglandin E2-induced cyclooxy-
genase-2 expression in human epidermoid carcinoma A-431 cells. J Invest Der-
matol in press
Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF: Speci¢c recruitment of
SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and ter-
mination of proliferative signals. Cell 80:729^738, 1995
Kuroda E, Sugiura T, Okada K, Zeki K,Yamashita U: Prostaglandin E2 up-regulates
macrophage-derived chemokine production but suppresses IFN-inducible pro-
tein-10 production byAPC. J Immunol 166:1650^1658, 2001
Lanzavecchia A: Licence to kill. Nature 393:413^414, 1998
Lee EH, RikihisaY: Protein kinase-A-mediated inhibition of gamma interferon-in-
duced tyrosine phosphorylation of Janus kinases and latent cytoplasmic trans-
duction factors in human monocytes by Ehrlichia cha¡eensis. Infect Immun
66:2514^2520, 1998
Majumder S, Zhou LS-H, Chaturvedi P, Babcock G, Aras S, Ransoho¡ RM: p48/
STAT-1a-containing complexes play a predominant role in induction of IFN-
g-inducible protein, 10 kDa (IP-10) by IFN-g alone or in synergy withTNF-a.
J Immunol 161:4736^4744, 1998
Meloche S, Pelletier S, Servant MJ: Functional cross-talk between the cyclic AMP
and Jak/STATsignaling pathways in vascular smooth muscle cells. Mol Cell Bio-
chem 212:99^109, 2000
Mukhopadhyay P, GeogheganTE, Patil RV, Bhattacherjee P, Paterson CA: Detection
of EP2, EP4, and FP receptors in human ciliary epithelial and ciliary muscle
cells. Biochem Pharmacol 53:1249^1255, 1997
Muller-Decker K, Scholz K, Marks F, Furstenberger G: Di¡erential expression of
prostaglandin H synthase isozymes during multistage carcinogenesis in mouse
epidermis. Mol Carcinog 12:31^41, 1995
Muller-Decker K, Reinerth G, Krieg P, et al: Prostaglandin-H-synthase isozyme ex-
pression in normal and neoplastic human skin. Int J Cancer 82:648^656, 1999
Narvaiza I, Mazzolini G, Barajas M, et al: Intratumoral coinjection of two adenoviruses,
one encoding the chemokine IFN-g-inducible protein-10 and another encoding
IL-12, results in marked antitumoral synergy. Immunol 164:3112^3122, 2000
Nishigaki N, Chang C-S, Ichikawa A, Negishi M: Cytoskeletal regulation of the
signal transduction of prostaglandin EP4 receptor. Biochim Piophys Acta
1391:110^116, 1998
Ohmori Y, HamiltonTA: Cooperative interaction between interferon (IFN) stimulus
response element and kB sequence motifs controls IFNg- and lipopolysacchar-
ide-stimulated transcription from the murine IP-10 promoter. J Biol Chem
268:6677^6688, 1993
Ohmori Y, Tebo J, Nedospasov S, Hamilton TA: kB binding activity in a murine
macrophage-like cell line. Sequence-speci¢c di¡erences in kB binding and
transcriptional activation functions. J Biol Chem 269:17684^17690, 1994
Ohmori Y, Schreiber RD, Hamilton TA: Synergy between interferon-g and tumor
necrosis factor-a in transcriptional activation is mediated by cooperation be-
tween signal transducer and activator of transcription 1 and nuclear factor kB.
J Biol Chem 272:14899^14907, 1997
Parfenova H, Balabanova L, Le¥er CW: Posttranslational regulation of cyclooxygen-
ase by tyrosine phosphorylation in cerebral endothelial cells. Am J Physiol
274:72^C81, 1998
1088 KANDA ANDWATANABE THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Rocchi S, Gaillard I, van Obberghen E, Chambaz EM, Vilgrain I: Adrenocortico-
trophic hormone stimulates phosphotyrosine phosphatase SHP2 in bovine
adrenocortical cells: phosphorylation and activation by cAMP-dependent pro-
tein kinase. Biochem J 352:483^490, 2000
Sales KJ, Katz AA, Davis M, et al: Cyclooxygenase-2 expression and prostaglandin
E2 synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/
paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin
Endocrinol Metab 86:2243^2249, 2001
Sales KJ, Katz AA, Howard B, Soeters RP, Millar RP, Jabbour HN: Cyclooxygen-
ase-1 is up-regulated in cervical carcinomas: autocrine/paracrone regulation of
cyclooxygenase-2, prostaglandin E receptors, and angiogenic factors by cy-
clooxygenase-1. Cancer Res 62:424^432, 2002
Schmid A,Thierauch K-H, SchleuningW-D, Dinter H: Splice variants of the human
EP3 receptor for prostaglandin E2. Eur J Biochem 228:23^30, 1995
Sengupta TK, Schmitt EM, Ivashikiv LB: Inhibition of cytokines and JAK-STAT
activation by distinct signaling pathways. Proc Natl Acad Sci USA 93:
9499^9504, 1996
Smith CJ, ZhangY, Koboldt CM, et al: Pharmacological analysis of cyclooxygenase-
1 in in£ammation. Proc Natl Acad Sci USA 95:13313^13318, 1998
SmithWL, DeWitt DL: Biochemistry of prostaglandin endoperoxide H synthase-1
and synthase-2 and their di¡erential susceptibility to nonsteroidal anti-in£am-
matory drugs. Semin Nephrol 15:179^194, 1995
Stolina M, Sharma S, Lin Y, et al: Speci¢c inhibition of cyclooxygenase 2 restores
antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Im-
munol 164:361^370, 2000
Strassmann G, Patil-Koota V, Finkelman F, Fong M, Kambayashi T: Evidence for
the involvement of interleukin-10 in the di¡erential deactivation of
murine peritoneal macrophages by prostaglandin E2. J Exp Med 180:
2365^2370, 1994
Tang Q, ChenW, Gonzales MS, Finch J, Inoue H, Bowden GT: Role of cyclic AMP
responsive element in the UVB induction of cyclooxygenase-2 transcription
in human keratinocytes. Oncogene 20:5164^5172, 2001
Thompson EJ, Gupta A,Vielhauer GA, Regan JW, Bowden GT:The growth of ma-
lignant keratinocyte depends on signaling through the PGE2 receptor EP1.
Neoplasia 3:402^410, 2001
Tjandrawinata RR, Dahiya R, Hughes-Fulford M: Induction of cyclo-oxygenase-2
mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer
75:1111^1118, 1997
van der Pouw Kraan CTM, Boeije LCM, Smeenk RJT, Wijdenes J, Aarden LA:
Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.
J Exp Med 181:775^779, 1995
Voila P: The role of cyclic AMP and oxygen intermediates in the inhibition
of cellular immunity in cancer. Cancer Immunol Immunother 43:1^9,
1996
Yin T, Shen R, Feng G-S, Yang Y-C: Molecular characterization of speci¢c interac-
tions between SHP-2 phosphatase and JAK tyrosine kinases. J Biol Chem
272:1032^1037, 1997
YoshidaT, Sakamoto H, Horiuchi T,Yamamoto S, Suematsu A, Oda H, KoshiharaY:
Involvement of prostaglandin E2 in interleukin-1a-induced parathyroid hor-
mone-related peptide production in synovial ¢broslasts of patients with rheu-
matoid arthritis. J Clin Endocrinol Metab 86:3272^3278, 2001
You M,Yu D-H, Feng G-S: Shp-2 tyrosine phosphatase functions as a negative reg-
ulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 19:2416^
2424, 1999
COX-2 INHIBITOR ENHANCES IP-10 PRODUCTION IN A431 1089VOL. 119, NO. 5 NOVEMBER 2002
